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Abstract
Cleft lip with/without cleft palate (CLP) is a common craniofacial malformation with
complex etiologies, reflecting both genetic and environmental factors. Most of the
suspected genetic risk for CLP has yet to be identified. To further classify risk loci and
estimate the contribution of rare variants, we sequenced the exons in 49 candidate
genes in 323 CLP cases and 211 nonmalformed controls. Our findings indicated that
rare, protein-altering variants displayed markedly higher burdens in CLP cases at rele-
vant loci. First, putative loss-of-function mutations (nonsense, frameshift) were signifi-
cantly enriched among cases: 13 of 323 cases (~4%) harbored such alleles within these
49 genes, versus one such change in controls (p = 0.01). Second, in gene-level analyses,
the burden of rare alleles showed greater case-association for several genes previously
implicated in cleft risk. For example, BHMT displayed a 10-fold increase in protein-
altering variants in CLP cases (p = .03), including multiple case occurrences of a rare
frameshift mutation (K400 fs). Other loci with greater rare, coding allele burdens in
cases were in signaling pathways relevant to craniofacial development (WNT9B, BMP4,
BMPR1B) as well as the methionine cycle (MTRR). We conclude that rare coding variants
may confer risk for isolated CLP.
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1 | INTRODUCTION
Although their causes are largely unknown, orofacial clefts are
suspected of being etiologically heterogeneous with both genetic and
nongenetic risk factors (Dixon, Marazita, Beaty, & Murray, 2011). Clinical
observations have long indicated that orofacial clefts should be classified
into at least two distinct phenotypic groups: cleft lip with or without cleft
palate (CLP) and cleft palate alone (CPO) (Fogh-Anderson, 1967). Collec-
tively, these are among the most common birth defects with a worldwide
prevalence of ~1 in 700 live births (WHO, 2001).
Genetic associations for CLP have been observed for several
genes, including IRF6, FGFR2, FOXE1, MSX1, NECTIN1, BMP4,
TBX22, and TGFa (Dixon et al., 2011) from either linkage analysis
or candidate gene studies. In addition, genome-wide association
studies (GWAS) have identified approximately 15 additional risk
loci (Beaty et al., 2010; Birnbaum et al., 2009; Grant et al., 2009;
Leslie et al., 2016; Ludwig et al., 2012; Mangold et al., 2010) with
some of these replicating in subsequent studies (e.g., – Jia et al.,
2015). For some of these loci, such as IRF6 and NOG, follow-up
sequencing efforts have identified compelling functional variants
as putative risk alleles (Leslie et al., 2015; Rahimov et al., 2008).
Interestingly, there is apparently little overlap between the most
significantly-associated GWAS regions and genes previously impli-
cated in CLP risk.
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This is probably indicative of the complex genetic etiologies
underlying the CLP phenotype and the difficulties detecting associ-
ated loci at genome-wide significance. Thus, there are likely to be
numerous additional genetic risk factors yet to be identified. Indeed,
the combined efforts of all these genetic approaches have been
extremely fruitful, yet still explain only a fraction of the population
burden of these human birth defects.
Several nongenetic factors also appear to contribute to cleft phe-
notypes (Mossey, Little, Munger, Dixon, & Shaw, 2009). Of particular
relevance to the current study is that maternal use of multivitamin
supplements containing folic acid in early pregnancy has been associ-
ated with decreased risk of CLP (Shaw, Lammer, Wasserman,
O'Malley, & Tolarova, 1995; Wilcox et al., 2007). Although some
reports do not observe a reduction in risk associated with maternal folate
supplementation (see Little et al., 2008), a recent meta-analysis indicated
a significant reduction in risk of CLP with maternal folic acid use
(Jahanbin, Shadkam, Miri, Shirazi, & Abtahi, 2018). Because of this folic
acid link, folate/one-carbon pathway genes have been a logical place to
look for risk variants (Blanton et al., 2011; Boyles et al., 2009; Marini
et al., 2016). However, many of the known common pathway SNPs have
been evaluated, yet the results are still somewhat unconvincing.
The exception to this seems to be the fairly consistent association of the
BHMT/BHMT2/DMGDH locus on Chromosome 5 with CLP observed in
a number of studies (Marini et al., 2016). Interestingly, while the locus
often shows association, the local SNPs driving the association can vary
between studies. Thus, the nature of the risk at this locus is still unclear.
In this study we hypothesized that some genetic risk for CLP lies
in rare variants and this has contributed to the lack of consistent find-
ings and attendant difficulty in unraveling risk alleles. Thus, we
sequenced the exons in 30 genes involved in folate metabolism in a
534-member case–control population to determine if rare variant
allele burden (in individual genes, subsets of genes, or the entire path-
way) correlated with phenotype. We also sequenced the coding
region of an additional 19 candidate genes (not related to folate
metabolism) that are involved in lip/palate development or previously
associated with CLP. Our results showed that, while there were no
folate pathway-wide trends in rare variant allele burden, two genes
involved in methionine synthesis (BHMT and MTRR) showed convinc-
ing case-associated trends for protein-altering variants. Likewise,
genes involved in BMP/WNT signaling (BMP4, BMPR1B, WNT9B),
which have been previously implicated in orofacial cleft development
(Juriloff, Harris, Mager, & Gagnier, 2014; Suzuki et al., 2009; Zhang
et al., 2002), displayed higher allele burdens in cases. CLP cases also
presented a greater number of loss-of-function alleles (frameshifts,
truncations) in this candidate gene set.
2 | METHODS
2.1 | Study population
This case–control study included data on deliveries that had estimated
due dates from 1995 to 2003. The study included live-born infants with
isolated CLP (N = 681), isolated CPO (N = 157), or without any
structural malformation (controls; N = 706). Because the goal of the
study was to determine whether rare coding variants in candidate
genes underlie risk for CLP, variant discovery by gene sequencing was
performed on an ethnically-mixed subset of this population comprising
323 CLP cases and 211 controls. A second group (358 CLP cases,
157 CPO cases, 485 controls) was used to further validate the CLP
case-association of a frameshift mutation in BHMT. See Table 1 for
race-ethnic breakdown of the study population.
Case information was abstracted from hospital reports and medi-
cal records following established procedures by the California Birth
Defects Monitoring Program (Croen, Shaw, Jensvold, & Harris, 1991).
Each medical record was further reviewed by a medical geneticist
(Edward J. Lammer, MD). Infants with trisomies were ineligible.
Nonmalformed control infants were selected randomly to represent
the birth population from which the cases were derived in selected
counties and birth periods. This study, including the collection and
use of archived newborn bloodspots, was approved by the California
State Committee for the Protection of Human Subjects as well as Insti-
tutional Review Boards at Stanford University and the University of
California, Berkeley.
2.2 | Genomic DNA isolation
Genomic DNA (gDNA) was available from newborn screening dried
blood spots obtained from linkage efforts made by the California Birth
Defects Monitoring Program. gDNA was extracted from dried blood
spots and whole-genome amplified using QIAmp DNA Mini kits and
Replica-G Midi amplification kits (Qiagen), respectively, as described
previously (Marini et al., 2011).
2.3 | Illumina paired-end sequencing of enriched
target exons
3–5 μg of whole-genome amplified DNA was used as starting material
for Illumina library construction and target exon capture with Sure Select
(Agilent) probes according to the Agilent SureSelectXT protocol (https://
www.agilent.com/cs/library/usermanuals/public/G7530-90000.pdf).
Briefly, DNA was fragmented with a Covaris sonicator, followed by end-
repair and A-tailing, then ligation of sequencing adaptors and PCR ampli-
fication. Amplified libraries were then used to perform target exon
capture by hybridization against a custom-made capture library of 120 bp
biotinylated oligonucleotide probes covering the 555 coding exons in
49 candidate genes of interest (Table S1). Probes (Agilent SureSelect)
were designed via the SureDesign web tool using the genomic coordi-
nates of target exons (genome build GRCh37/hg19). To ensure capture
and coverage of the entire coding region and splice sites, probes were
designed with an additional 50 bp “pad” that covered intronic regions
adjacent to coding exons or, in the case of the first or last coding exon,
covered the 50- or 30- untranslated regions. Following hybridization and
streptavidin capture of enriched exons, captured libraries were barcoded
with 6 bp tags with an additional round of PCR, quantified, and 12–16
sample libraries were pooled for 100 bp paired-end sequencing on the
Illumina HiSeq (v3 chemistry).
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2.4 | Read mapping and variant filtering
Raw sequence files (FASTQ) were imported into CLC Genomics
Workbench (v.6; Qiagen) and mapped onto the human genome
(GRCh37/hg19). Only full-length, paired, uniquely-mapping reads with
<= 3 mismatches were used for variant calling. Variants with depth of
coverage <30, or with genotype quality scores <25, were excluded. In
addition, alleles not observed on both strands (with a minimum
frequency ≥ 0.1) or with allelic imbalances (heterozygote genotype
calls with one allele observed with frequency < 0.25 or homozygote
alleles observed with frequency < 0.85) were also excluded. After
compilation of the dataset, positions not covered in at least 95% of
the cases or controls were then removed.
2.5 | Variant calling accuracy
The accuracy of the variant calls in the filtered dataset was evaluated in
two ways: (a) the concordance of genotype calls by Illumina sequencing
and by TaqMan allelic discrimination assays (described in Marini et al.,
2016) was determined for 8,537 variant calls (mostly common alleles) in
476 samples and (b) confirmation by Sanger sequencing for the subset
of rare variants in genes with striking case-related trends (~15% of all
protein-altering variants identified in the study). Verification sequencing
was performed on original bloodspot gDNA preparations, prior to
whole-genome amplification, using amplicon-specific M13-capped PCR
primers designed by VariantSEQr methodology (ThermoFisher) and
deposited into the NCBI probe database (https://www.ncbi.nlm.nih.
gov/probe/docs/projvariantseqr/). Each sample for verification had a
corresponding negative control for comparison.
2.6 | Analyses
To estimate the contribution of rare (MAF < 1%) coding variants
(for which there may only be a single occurrence) to CLP risk, a simple
allele burden test was applied on a gene-by-gene basis to highlight
genes with prominent case–control skews. Alleles were summed by
gene (or groups of genes) and case–control associations were tested
by Fisher's exact test based on genotype distributions (i.e., carrier
frequency). Although, this cannot be used as a strict test for associa-
tion, statistical differences in case or control representation are readily
observed with this metric. For common polymorphisms, variants were
treated as categorical variables, that is, homozygous wild-type as ref-
erent versus heterozygous or homozygous variant. Odds ratios and
95% confidence intervals were used to estimate risks.
3 | RESULTS
3.1 | Dataset definition, variant calling, and quality
control
We took a candidate gene approach, with a focus on folate pathway
genes, to investigate the potential contribution of rare coding variants
to CLP risk by determining whether putative loss-of-function alleles
or rare allele burdens in certain genes (or pathways) correlated with
phenotype. Thus we sequenced the coding exons and exon/intron
boundaries in 30 genes related to folate metabolism and 19 additional
genes involved in craniofacial development in a case–control study
(Table 1). The full list of genes queried, including exon annotations
and coverage statistics are in Table S1. 532 coding exons out of the
TABLE 1 Populations used in study
A. Discovery population
Race/ethnicity
CLP cases
(collective percentage)
Controls
(collective percentage)
Asian 35 (10.8) 25 (11.8)
Black 13 (4.0) 8 (3.8)
White, Hispanic 190 (58.8) 126 (59.7)
White, non-Hispanic 79 (24.5) 48 (22.7)
Other 6 (1.9) 4 (1.9)
TOTAL 323 211
B. Validation population
Race/ethnicity
CLP cases
(collective percentage)
CPO cases
(collective percentage)
Controls
(collective percentage)
Asian 41 (11.5) 18 (11.5) 41 (8.5)
Black 9 (2.5) 9 (5.7) 29 (6.0)
White, Hispanic 188 (52.5) 58 (36.9) 231 (47.6)
White, non-Hispanic 54 (15.1) 32 (20.4) 83 (17.1)
Other 6 (1.7) 1 (0.6) 5 (1.0)
No race reported 59 (16.5) 39 (24.8) 96 (19.8)
Native American 1 (0.3)
TOTAL 358 157 485
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555 targeted for enrichment in these 49 genes (96%) passed quality
control for adequate coverage and sequence quality. Mean coverage
for each of these 532 exons was similar between the case group and
the control group, indicating each group was sequenced with equal
efficiency (Figure S1).
Variants were called in exons and in intron regions within 10 bp
from exon/intron junctions as described in Methods. To evaluate the
overall quality and accuracy of the variant calls, we performed two
types of independent assessments on different subsets of variants. In
the first, we established the concordance between the genotypes
called from Illumina sequencing with those obtained from TaqMan
allelic discrimination assays for many multiply-occurring loci (i.e., not
singletons) using TaqMan assays previously described (Marini et al.,
2016). 91 variant positions in 24 genes were compared in 476 samples.
Out of 8,537 variant calls, we observed 99.7% concordance between
the two methods (Table S2).
In a second quality-control check, we evaluated all putative
loss-of-function alleles (frameshifts and truncations), and all rare
and singleton missense variant calls from genes whose alleles
showed higher case representation, by exon-specific Sanger res-
equencing (see Section 2). Out of 95 tested variants, all were confirmed
except one frameshift in a low complexity region, which was subse-
quently removed (Table S3). Based on these analyses, we are confident
in the sequencing accuracy of the data, necessary for rare variant
genotyping.
The final analytical dataset contained data for 773 variant posi-
tions: 285 synonymous, 380 protein-altering, and 108 noncoding vari-
ants. One hundred fifty-five (54%) of the synonymous alleles were
singletons, whereas 243 (64%) of the protein-altering alleles were
singletons. The complete list of annotated variants, allele frequencies,
and case–control distributions are in Table S4.
3.2 | Common allele associations
Although our focus was on the distribution of rare coding alleles,
sequence data also provided information on associations of more com-
mon variants. We observed a small number of nominally significant
associations that are in agreement with previous studies. For example,
association of nonsynonymous SNPs in DMGDH (S279P, homozygous
OR = 0.5 [0.3–0.9], p = .022) and ALDH1L1 (I812V, heterozygous
OR = 2.7 [1.3–5.5], p = .008) have been reported previously (Boyles
et al., 2009; Marini et al., 2016).
By far, the strongest statistically significant signal of any variant
with high enough frequency to calculate was the nonsynonymous
SNP V274I in IRF6 (heterozygous OR = 0.5 (0.3–0.7), p = 4E−04;
homozygous OR = 0.5 (0.2–0.9), p = .046), a well-studied polymor-
phism in orofacial cleft studies with numerous reported associa-
tions (Beaty, Marazita, & Leslie, 2016). A second IRF6 synonymous
SNP (S153S) was also significantly associated in homozygotes
(OR = 0.6 [0.4–0.9], p = .02). Finally, there were two linked synony-
mous SNPs in the VANGL2 gene (G445G and P467P; heterozygous
OR = 1.8 [1.2–2.7], p = .004), which has not previously been associ-
ated with CLP.
Odds ratios were calculated only from genotype frequencies in
the entire, ethnically diverse population, and not in ethnically strati-
fied sub-populations, because this study was not sufficiently powered
for such analyses. Our focus was on rare variants which are often
impervious to meaningful ethnic stratification analyses owing to the
infrequency of occurrence. However, we have ensured that the race-
ethnic breakdown was approximately the same in case and control
groups (Table 1).
3.3 | Association of putative loss-of-function alleles
The candidate gene set interrogated in this study is a mix of both
folate pathway genes and genes implicated in cleft occurrence
because of their roles in craniofacial development. Thus, this set was
enriched for potential cleft risk genes over what might be considered
in a broader sampling of the exome. Therefore, it is noteworthy that
we observed a significant enrichment of putative loss-of-function
alleles (frameshifts, truncations) in CLP cases: 13 cases harbored one
such allele from this gene set versus only 1 control (Fisher's exact
p = .01; Table 2). All alleles in Table 2 were seen only once in this popu-
lation except for the deletion/frameshift at Lysine 400 in BHMT
(K400fs), which was seen in four cases of differing ethnicity. It is further
noteworthy that several of the genes represented in Table 2 (BHMT,
DMGDH, MTRR, IRF6) have displayed significant CLP associations in
multiple studies (see Section 4). It should be emphasized that functional
impact of these alleles is only inferred, though they represent good can-
didates for mutations of consequence for cleft risk.
3.4 | Folate pathway variation
Despite numerous epidemiological studies suggesting that maternal
folic acid supplementation may modify risk for CLP, common SNP
association studies with folate/one-carbon pathway variants have not
been definitive in linking pathway loci to phenotype. Suggestive evi-
dence exists for several loci from this group (e.g., Blanton et al., 2011;
Boyles et al., 2009; Marini et al., 2016), though reproducibility across
populations and small effect sizes remain problematic. The role of
rare variants in folate pathway genes has not been adequately queried
and may account for genetic risk yet to be identified. Indeed, the
folate/one-carbon pathway may be particularly susceptible to the aggre-
gate mutation burden throughout the pathway, since there are many co-
dependent and interacting components. Thus, we hypothesized that the
aggregate burden of rare variants in the folate pathway (or related genes
in pathway sub-compartments) may confer risk for CLP and help explain
the folate link. We have found such pathway analyses useful in under-
standing the role of folate pathway variation, common and rare, with
respect to neural tube defect risk (Marini et al., 2011).
By allele summing of rare variants (defined here as MAF < 1%), the
group of folate/one-carbon pathway genes (N = 30) did not show an
increased aggregate burden of either synonymous mutations (case aggre-
gate allele frequency = 0.27, control aggregate allele frequency = 0.28;
p = .57, Mann–Whitney test) or intron mutations within 10 bp of the
exon boundary (case aggregate allele frequency = 0.12, control aggregate
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allele frequency = 0.10; p = .34, Mann–Whitney test) that might
distinguish cases from controls. There was as slight increase in aggre-
gated protein-altering allele frequency for cases (case aggregate allele
frequency = 0.38, control aggregate allele frequency = 0.31); though the
distributions were not significantly different (p = .08).
Upon sub-dividing pathway genes into compartments with metabol-
ically related genes (e.g., – purine synthesis, see (Marini et al., 2011)), it
became obvious that the strongest case-associated signals for rare,
protein-altering variants were restricted to two genes involved in methi-
onine synthesis: BHMT (betaine-homocysteine methyl transferase) and
MTRR (methionine synthase reductase), both of which are necessary for
the remethylation of homocysteine to methionine (Figure 1, Table 3). In
addition to the four case occurrences of the K400fs allele in BHMT, non-
synonymous variants were found in an additional 7 cases and only a sin-
gle control (Fisher's exact p = .03). Similarly, protein-altering variants for
MTRRwere found in 13 cases versus 2 controls (p = .06).
Using a minor allele frequency cutoff of 5%, rather than 1%,
yielded similar folate pathway-wide trends: there were no significant
differences in the aggregate burden of noncoding variants (p = .38) or
synonymous variants (p = .81), but the aggregate burden of protein-
altering variants was significantly higher in cases (case aggregate allele
frequency = 0.63, control aggregate allele frequency = 0.50; p = .02).
No additional folate pathway genes, besides BHMT and MTRR, dis-
played significant case–control differences.
3.5 | Individual gene analysis
For each of the 49 genes in this study, rare synonymous or protein-altering
variants were collapsed by summing and genotype frequencies for this
allele burden metric were subject to Fisher's exact testing (Figure 1). Con-
sistent with the absence of a signal seen from synonymous variation in the
folate pathway, PTCH1 was the only gene with a statistically significant
altered case–control distribution of rare synonymous variants: case carrier
frequency (0.20) was approximately twofold higher than that in controls
(0.12; p = .03).
In contrast, there were several genes with higher carrier frequency
of protein-altering variants in cases with more striking case–control
differentials (Figure 1 and Table 3). In addition to the BHMT and MTRR
allele distributions discussed above, there were 13 case appearances
(all heterozygotes) of missense alleles in the WNT9B gene, versus only
one missense occurrence in controls (p = .01). One missense change,
A126T, was found exclusively in three cases. Likewise, in the BMPR1B
gene, which encodes a receptor for bone morphogenetic protein (BMP)
secreted ligands, there were nine occurrences of missense alleles in
cases without a single observation in controls (p = .01). Also noteworthy
is the BMP4 gene, which encodes a specific, secreted bone morphoge-
netic ligand involved in embryonic head development. We observed six
different missense alleles of BMP4 in case heterozygotes versus zero
protein-altering variants in controls (p = .09). These last three genes
were included based on their roles in craniofacial development (and, in
some cases, isolated cleft risk (Juriloff et al., 2014; Suzuki et al., 2009;
Yang et al., 2017)). Thus, it was interesting to see striking accumulation
of rare variation in CLP cases.
3.6 | Replication of the case association of BHMT
K400fs in a second population
As described above, we observed multiple case occurrences of a frame-
shift (delA) at lysine 400 in BHMT. This lesion occurs only 7 amino acids
from the C-terminus and is inferred (by nucleotide sequence) to replace
these last 7 residues (KQKFKSQ) with 13 different amino acids
(NKNSNHSSLDRSYF). Thus, the functional impact of this mutation is
TABLE 2 Putative loss-of-function alleles
Gene Variant Typea Case appearanceb Control appearanceb
BHMT K400fs Deletion/frameshift Hispanic
Hispanic
Non-Hispanic, White
Non-Hispanic, White
DMGDH W495termb SNV/stop-gain Hispanic
GGH L190fs Insertion/frameshift Non-Hispanic, White
IRF6 Q112termb SNV/stop-gain Non-Hispanic, White
MTRR R386termb SNV/stop-gain Non-Hispanic, White
SARDH R457termb SNV/stop-gain Hispanic
SARDH R514termb SNV/stop-gain Hispanic
SP8 S261termb SNV/stop-gain Hispanic
SHMT1 R99termb SNV/stop-gain Hispanic
SHMT1 R207termb SNV/stop-gain Asian
SHMT1 Y457termb SNV/stop-gain Asian
TOTAL 13 1
aAbbreviation: SNV, single nucleotide variation.
bEthnicity of newborn.
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difficult to confidently discern. We took the same set of Exon 8-specific
resequencing primers used for variant verification (see Section 2) to
genotype-by-sequence this variant in a second, case–control population
(validation population in Table 1). We observed this variant as a hetero-
zygote three additional times in the validation population: two additional
CLP cases (one Hispanic, one non-Hispanic, White) and one control
(non-Hispanic, White). We did not observe this variant in the cleft palate
only (CPO) subset of this population (N = 157).
4 | DISCUSSION
In this study we took a candidate gene approach to investigate the
potential contribution of rare coding variants to CLP risk, with the
reasoning that at least some of the genetic risk not yet identified in
common allele studies may reside in rare variation. The contribution
of rare, coding mutations in CLP risk has been previously suggested in
multiple sequencing studies (Al Chawa et al., 2014; Leslie & Murray,
2013; Suzuki et al., 2009), though this has only recently begun to be
systematically addressed (Aylward et al., 2016; Leslie et al., 2017). We
focused on 49 candidate genes with an emphasis on nearly complete
coverage of folate metabolism (N = 30 genes), since rare folate pathway
variants have not been explored for CLP risk, particularly when con-
sidered in aggregate across the pathway or within related genesets.
We queried 19 additional genes unrelated to folate metabolism, that
have been implicated in disease risk by vertebrate models of clefting
(e.g., WNT9B) or craniofacial development, or by human genetic associa-
tion studies (e.g., BMP4, IRF6). From a catalog of the full spectrum of alle-
lic variation within the coding regions of this target-enriched gene set, we
found two lines of evidence for the contribution of rare variants to CLP
risk: (a) cases displayed an overabundance of putative loss-of-function
alleles at these loci and (b) several mechanistically relevant genes showed
similar case over-representation for protein-altering variants, in general.
F IGURE 1 The occurrences
of all rare coding region variants
(MAF <1.0%) were summed on a
gene-by-gene basis to yield the
total allele burden for
synonymous (left panel) and
protein-altering (middle panel)
variants. Protein-altering variants
encompass frameshifts,
truncations, and missense alleles.
Allele sum frequency is the carrier
frequency (% heterozygote
carriers) for each gene. p values
were calculated (right panel)
based on 2 × 2 Fisher's exact test
of the summed carrier frequency
for synonymous and protein-
altering changes and expressed as
−log p [Color figure can be
viewed at wileyonlinelibrary.com]
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4.1 | Folate pathway variation: Methionine cycle
genes
We sequenced the majority of folate/one-carbon pathway genes,
which enabled us to interpret rare variation in the context of pathway
function. This approach was useful in identifying folate-related risk
signatures for neural tube defects (Marini et al., 2011). While we did
not see any pathway-wide trends in allele burdens or distributions
that significantly differentiated CLP cases from controls, we did
observe two genes directly involved in methionine biosynthesis with a
considerable over-abundance of protein altering variants in cases:
BHMT and MTRR (Table 3). Betaine-homocysteine methyltransferase
(BHMT) and Methionine synthase reductase (MTRR) are both
involved in the methylation of homocysteine to yield methionine.
They operate in different pathways; however, and while BHMT uti-
lizes methyl groups generated from choline catabolism, the reaction
involving MTRR utilizes 5-methyl-tetrahydrofolate.
The CLP-association of rare variants at BHMT is intriguing for two
reasons: First, this locus, which is part of the metabolically-related
BHMT/BHMT2/DMGDH gene cluster on chromosome 5, is one of the
most consistently associated loci in one-carbon pathway gene-CLP
association studies (reviewed in Marini et al., 2016). However, while
the locus is often associated, the regional SNPs that drive the associa-
tion can be different, as can the directionality of risk (i.e., whether
odds ratios are < or >1). We postulated that these phenomena may
reflect the contribution of underlying rare variants at this locus (which
may occur on the haplotype of the major or minor allele of a nearby
common variant) as has been previously suggested for clefts (Leslie &
Murray, 2013) and as has been seen for regions highlighted by GWAS
studies (Leslie et al., 2015). The distribution of rare variants at BHMT
is also intriguing because of the appearance of a frameshift mutation
(K400fs) that was observed in multiple CLP cases (discussed below).
The increased mutation burden in these two genes brings atten-
tion to homocysteine clearance as relevant for modifying CLP risk,
which has been previously suggested (Kumari, Ali, Sukla, Singh, &
Raman, 2013; Wong et al., 1999). Furthermore, interference of methio-
nine synthesis suggests perturbations in cellular methylation reactions
(via S-adenosylmethionine levels), which may manifest in DNA methyla-
tion changes associated with CLP, as has been observed (Alvizi et al.,
2017; Sharp et al., 2016).
4.2 | Putative loss-of-function alleles
Within this target gene set, CLP cases displayed a significantly greater
frequency of indel frameshift and truncation alleles (p = .01; Table 2).
One of the most intriguing alleles is the K400 fs deletion allele
of BHMT, which was observed in four cases (both Hispanic and
non-Hispanic, White) but not in controls in the discovery popula-
tion. A second, validation population revealed two additional CLP
case occurrences and one control occurrence. Although the functional
impact of this allele is yet to be determined, its observance in multiple
cases is noteworthy particularly because global population frequencies
of this variant are estimated at 2.2E−04 in the Genome Aggregation
Database (www.gnomad.broadinstitute.org), substantially lower than
our overall case frequency (MAF = 0.004 in all cases queried). The
low number of occurrences for this allele does not allow an effective
statistical test in populations of this size, nevertheless, multiple case
observations in two separate populations is higher than expected
TABLE 3 Genes with strongest case representations of rare,
protein-altering variants
Gene
Case appearancesa Control appearancesa
Variant # Variant #
BHMT D105N 1 V122M 1
E136K 1
P197S 3
G199S 2
K400fs 4
BMP4 D56E 1
R139H 1
R162Q 1
R223H 1
R226Q 1
R269Q 1
BMPR1B P23S 1
V67D 1
V140I 2
R149W 1
Q153R 1
M301V 1
R371Q 1
R413S 1
MTRR H36Y 1
N218K 1
V265G 1
T286M 3
I290T 1
K352N 1
R386a 1
R418Q 1
T490A 2 T490A 1
V674A 1 V607I 1
WNT9B A42V 1
Q47R 2
R94Q 2 R94Q 1
N99S 1
A126T 3
K184N 1
R222H 1
S244L 2
aAll variants were seen as heterozygotes; only MTRR T490A andWNT9B
R94Q were seen in both cases and controls.
1266 MARINI ET AL.
based on the reported global MAF. It should be noted that this variant
is described as low-confidence in the gnomAD database. However, the
signal was strong in our data and all instances clearly replicated in verifi-
cation Sanger sequencing (see Figure S2, for example). Thus, we are
confident of these variant calls.
In addition to BHMT, we also observed case-associated trunca-
tions in several other genes relevant to methyl donor production
(MTRR R386*, DMGDH W495*, and SARDH R457*, R514*). Based on
protein lengths (MTRR 698aa, DMGDH 866aa, SARDH 918aa), these
changes are likely to be consequential. BHMT, DMGDH (dimethyl-
glycine dehydrogenase), and SARDH (sarcosine dehydrogenase) are
sequential enzymatic steps in the catabolism of choline to glycine,
which generates methyl donors for cellular methylation reactions as
noted above. Interestingly, increased intake of choline in the maternal
diet has been associated with decreased CLP risk (Shaw, Carmichael,
Laurent, & Rasmussen, 2006).
Outside of folate/one-carbon pathway genes, two case trunca-
tions were observed in genes previously implicated in orofacial cleft
risk: IRF6 Q112* and SP8 S261*. Significant associations of IRF6 with
CLP have been reported in multiple populations (Beaty et al., 2016)
and may account for up to 12% of the genetic component of CLP in
some populations (Zucchero et al., 2004). SP8 is a transcription factor
in which mutations display severe craniofacial malformations including
cleft palate (Kasberg, Brunskill, & Steven Potter, 2013).
4.3 | Genes unrelated to folate metabolism
Three additional genes involved in craniofacial development also
displayed striking case-overrepresentation of missense variants:
BMP4, BMPR1B, and WNT9B (Table 3). WNT9B and BMP4 are
secreted signaling proteins regulating critical interacting signaling
pathways in craniofacial development (Alexander, Piloto, Le Pabic, &
Schilling, 2014). BMPR1B encodes a receptor for BMP4 and other bone
morphogens. Significantly, all three genes have been implicated in
orofacial cleft risk.
BMP4 is one of the most promising candidate genes for CLP, with
evidence shown in animal experiments (e.g., Liu et al., 2005) and asso-
ciation studies (e.g., Chen et al., 2014). Furthermore, a gene sequenc-
ing study (Suzuki et al., 2009) demonstrated that rare BMP4 coding
mutations were enriched in CLP cases at similar frequencies to those
shown here. Only the R162Q case-specific nonsynonymous mutation
was identified in both studies.
Although rare coding variants inWNT9B or BMPR1B have yet to be
reported as contributing to CLP risk, these genes have been implicated
by other means. WNT9B is at a locus identified in a genome-wide asso-
ciation study (Yu et al., 2017) and a murine model demonstrated that
transcriptional repression of Wnt9b via epigenetic mechanisms leads to
the development of cleft lip in mouse embryos (Juriloff et al., 2014).
BMPR1B is at a locus associated with CLP by linkage analysis (Schultz
et al., 2004) and has been identified as a genetic cause of Pierre Robin
syndrome, in which cleft palate is a prominent component (Yang
et al., 2017).
4.4 | Rare versus private mutations
Of all the variants described in Tables 2 and 3, most have been seen
before in the population, as measured by their annotation in the Genome
Aggregation Database (www.gnomad.broadinstitute.org). Novel variants
in this study are restricted to two missense variants in BMPR1B (P23S
and V67D), and three putative loss-of-function truncations (DMGDH
W495*, IRF6 Q112*, SP8 S261*). The frameshift allele in GGH (insT at
L190) was previously observed once in over 250,000 alleles. All others
have multiple occurrences, though at significantly lower frequencies in
the general population than seen here in CLP cases. However, most of
our observations are singletons (with a notable exception being the
K400fs allele of BHMT), precluding true case frequency estimates.
If rare alleles such as these contribute to CLP risk, it is likely that
they will be uncovered only by sequencing/discovery approaches rather
than array-based genotyping, even for large array sizes. Furthermore,
the degree to which risk loci identified by traditional association studies
will reveal loci with underlying rare variant burdens (as we have
suggested for the BHMT/BHMT2/DMGDH gene cluster) is still unknown.
For example, Leslie et al. (2015) failed to find convincing evidence of
CLP-related rare allele burdens at GWAS loci in 1500 trios. It may be
that the underlying genetic heterogeneity for CLP risk is sufficiently
complex that many such burdened loci do not display genome-wide sig-
nificance in traditional association studies. Indeed, nearly all variants dis-
cussed here were heterozygous and none co-occurred with any others.
Thus, if they are involved in CLP risk, they must be part of a more com-
plex etiology.
4.5 | Strengths/limitations
Strengths of this study lie in the case–control design, which allows for a
broader sampling of rare alleles than family-based studies, and the
assurance of accuracy in the sequencing data, which is essential for rare
variant discovery. Although CLP risk loci identified in this study are con-
sistent with previous studies and with biological mechanisms, the study
is limited by both sample size and the ability to draw reliable associa-
tions from rare variants. Thus, statistical measures used here are not a
true measure of association but of highlighting genes with differential
case burdens. Therefore, replication of these findings in additional,
larger populations is needed to afford significance of the potential asso-
ciations observed here.
Another limitation is that the functional impact of variants is
unknown. We have assumed that the striking mutation skews are
indicative of a contribution to CLP etiology. In support of this assump-
tion, we used two computational algorithms to predict the functional
impact of all missense mutations identified from the five genes in
Table 3: CADD (Rentzsch, Witten, Cooper, Shendure, & Kircher,
2019) and PolyPhen2 (Adzhubei et al., 2010). Both tools estimated
that mutations occurring only in cases were significantly enriched for
deleterious changes when compared against variants in the same
genes seen in controls (Figure S3). Nevertheless, given the potential
fallibility of predictive algorithms, we await empirical determination of
functional impact to enable more robust mechanistic conclusions with
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respect to phenotype. Despite these limitations, these results are
consistent with several reports implicating rare coding variants in CLP
risk. The clustering of risk genes reinforces focus on one-carbon
metabolism and the BMP/WNT signaling pathways.
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